HEMO.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold HEMO.L in your mock portfolio yet.
The company is currently loss-making, as indicated by its negative EPS and PE ratio. This suggests the business has yet to achieve sustainable profitability and is likely still in a capital-consuming, development-focused phase. Without evidence of improving earnings trends, the financial profile remains high risk.
The stock has risen 18.1% over the last month, showing recent positive momentum, but the RSI near 46 suggests neither overbought nor oversold conditions. Trading above the 200-day moving average points to a modestly constructive longer-term trend, though the move is not extreme. Overall, technicals are balanced, with a slight positive tilt but no strong directional signal.
Social media presence is modest and growth is largely flat, with only minor changes across platforms. The small follower base and minimal growth imply limited retail awareness and engagement, but not a clear deterioration in sentiment. In the absence of strong positive or negative alternative data trends, these signals are broadly neutral for the stock.
Despite a recent price increase and a technically constructive position above the 200-day moving average, Hemogenyx Pharmaceuticals Plc remains fundamentally constrained by negative earnings and a lack of demonstrated profitability. Alternative data signals show only modest and mostly flat engagement, offering little support for a strong growth narrative. Overall, the risk profile appears elevated, with the investment case still heavily dependent on future execution and milestones rather than current financial strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: